Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes

Tonolo, G. ; Velussi, M. ; Brocco, E. ; Abaterusso, C. ; Carraro, A. ; Morgia, G. ; Satta, A. ; Faedda, R. ; Abhyankar, Avinash LU and Luthman, Holger LU , et al. (2006) In Kidney International 70(1). p.177-186
Abstract
The factors determining the course of glomerular fitration rate (GFR) and albumin excretion rate (AER) and the expression of mRNA of slit diaphragm (SD) and podocyte proteins in microalbuminuric, hypertensive type II diabetic patients are not fully understood. GFR, AER, and SD protein mRNA were studied in 86 microalbuminuric, hypertensive, type II diabetics at baseline and after 4-year random double-blind treatment either with 40 mg simvastatin (Group 1) or with 30 g cholestyramine (Group 2) per day. Both groups had at baseline a GFR decay per year in the previous 2-4 years of 3 ml/min/1.73 m(2). Both Groups 1 and 2 showed a significant decrease of low-density lipoprotein cholesterol levels after simvastatin and cholestyramine treatment (P... (More)
The factors determining the course of glomerular fitration rate (GFR) and albumin excretion rate (AER) and the expression of mRNA of slit diaphragm (SD) and podocyte proteins in microalbuminuric, hypertensive type II diabetic patients are not fully understood. GFR, AER, and SD protein mRNA were studied in 86 microalbuminuric, hypertensive, type II diabetics at baseline and after 4-year random double-blind treatment either with 40 mg simvastatin (Group 1) or with 30 g cholestyramine (Group 2) per day. Both groups had at baseline a GFR decay per year in the previous 2-4 years of 3 ml/min/1.73 m(2). Both Groups 1 and 2 showed a significant decrease of low-density lipoprotein cholesterol levels after simvastatin and cholestyramine treatment (P < 0.01). No change from base line values was observed as for hs-C-reactive protein and interleukin-6. A significant decrease of 8-hydroxydeoxyguanosine urinary excretion was observed after simvastatin treatment. GFR did not change from baseline with simvstatin, whereas a decrease was observed with cholestyramine treatment ( simvastatin vs cholestyramine: -0.21 vs -2.75 ml/min/ 1.73 m(2), P < 0.01). AER decreased in Group 1 (P < 0.01), but not in Group 2 patients. Real-time polymerase chain reaction measurement of mRNA SD proteins (CD2AP, FAT, Actn 4, NPHS1, and NPHS2) significantly increased in kidney biopsy specimens after simvastatin, but not cholestyramine treatment. Simvastatin, but not cholestyramine, 4-year treatment maintains steady patterns of GFR, and improves AER and expression of SD proteins in type II diabetes, despite similar hypocholesterolemic effects in circulation. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
C-reactive protein, type II, diabetes, oxidized-LDL, slit diaphragm proteins, podocytes, rate, glomerular filtration, microalbuminuria, simvastatin, cholestyramine
in
Kidney International
volume
70
issue
1
pages
177 - 186
publisher
Nature Publishing Group
external identifiers
  • pmid:16710349
  • wos:000238969300032
  • scopus:33745711911
ISSN
1523-1755
DOI
10.1038/sj.ki.5001515
language
English
LU publication?
yes
id
90d470c1-6af4-4650-9f11-d000e543ff7f (old id 686389)
date added to LUP
2016-04-01 16:50:00
date last changed
2021-08-25 02:28:27
@article{90d470c1-6af4-4650-9f11-d000e543ff7f,
  abstract     = {The factors determining the course of glomerular fitration rate (GFR) and albumin excretion rate (AER) and the expression of mRNA of slit diaphragm (SD) and podocyte proteins in microalbuminuric, hypertensive type II diabetic patients are not fully understood. GFR, AER, and SD protein mRNA were studied in 86 microalbuminuric, hypertensive, type II diabetics at baseline and after 4-year random double-blind treatment either with 40 mg simvastatin (Group 1) or with 30 g cholestyramine (Group 2) per day. Both groups had at baseline a GFR decay per year in the previous 2-4 years of 3 ml/min/1.73 m(2). Both Groups 1 and 2 showed a significant decrease of low-density lipoprotein cholesterol levels after simvastatin and cholestyramine treatment (P &lt; 0.01). No change from base line values was observed as for hs-C-reactive protein and interleukin-6. A significant decrease of 8-hydroxydeoxyguanosine urinary excretion was observed after simvastatin treatment. GFR did not change from baseline with simvstatin, whereas a decrease was observed with cholestyramine treatment ( simvastatin vs cholestyramine: -0.21 vs -2.75 ml/min/ 1.73 m(2), P &lt; 0.01). AER decreased in Group 1 (P &lt; 0.01), but not in Group 2 patients. Real-time polymerase chain reaction measurement of mRNA SD proteins (CD2AP, FAT, Actn 4, NPHS1, and NPHS2) significantly increased in kidney biopsy specimens after simvastatin, but not cholestyramine treatment. Simvastatin, but not cholestyramine, 4-year treatment maintains steady patterns of GFR, and improves AER and expression of SD proteins in type II diabetes, despite similar hypocholesterolemic effects in circulation.},
  author       = {Tonolo, G. and Velussi, M. and Brocco, E. and Abaterusso, C. and Carraro, A. and Morgia, G. and Satta, A. and Faedda, R. and Abhyankar, Avinash and Luthman, Holger and Nosadini, R.},
  issn         = {1523-1755},
  language     = {eng},
  number       = {1},
  pages        = {177--186},
  publisher    = {Nature Publishing Group},
  series       = {Kidney International},
  title        = {Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes},
  url          = {http://dx.doi.org/10.1038/sj.ki.5001515},
  doi          = {10.1038/sj.ki.5001515},
  volume       = {70},
  year         = {2006},
}